microRNA inhibitors for use in treating metabolic diseases

A composition comprising an inhibitor of miR-379 and an inhibitor of miR-541,

• wherein miR-379 has the nucleotide sequence of SEQ ID NO:
• 1, and miR-541 has the nucleotide sequence of SEQ ID NO:
• 2 or SEQ ID NO:
• 6,
• wherein the inhibitor of miR-379 comprises a nucleotide sequence of at least 15 nucleotides in length that is complementary to, and hybridizes to, miR-379, and wherein the inhibitor of miR-541 comprises a nucleotide sequence of at least 15 nucleotides in length that is complementary to, and hybridizes to, miR-541,
• wherein at least one of the inhibitors comprises a chemical modification of the nucleic acid sequence selected from the group consisting of nucleic acid analogs comprising N-acetylgalactosamine (GalNAc), phosphorothioate DNA (PS), 2′-O-methyl RNA (OMe), 2′-O-methoxy-ethyl RNA (MOE), peptide nucleic acid (PNA), N3′-P5′-phosphoroamidate (NP), 2′-fluoro-arabino nucleic acid (FANA), morpholino phosphoroamidate (MF), cyclohexene nucleic acid (CeNA), and tricycleDNA (tc-DNA), and
• wherein at least one of the inhibitors is comprised by a delivery vehicle selected from the group consisting of polyethylene imine (PEI), cationic liposomes, silica nanoparticles, PEGylated PLGA, and neutral lipid.